Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arqule Inc (ARQL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 452,670
  • Shares Outstanding, K 95,500
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,200 K
  • 36-Month Beta 1.10
  • Price/Sales 109.34
  • Price/Cash Flow N/A
  • Price/Book 44.87

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.53 +32.86%
on 05/22/18
6.07 -22.73%
on 06/06/18
+1.07 (+29.56%)
since 05/21/18
3-Month
2.40 +95.42%
on 05/07/18
6.07 -22.73%
on 06/06/18
+1.82 (+63.41%)
since 03/21/18
52-Week
0.94 +398.94%
on 08/21/17
6.07 -22.73%
on 06/06/18
+3.54 (+307.83%)
since 06/21/17

Most Recent Stories

More News
ArQule Presents Results from Ongoing Phase 1 Dose Escalation Study of its Reversible BTK Inhibitor, ARQ 531

ArQule, Inc. (Nasdaq:ARQL) today is presenting preliminary results from the Company's Phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible inhibitor of...

ARQL : 4.69 (-1.05%)
ArQule to Present at The JMP Securities Life Sciences Conference on June 21, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at...

ARQL : 4.69 (-1.05%)
Options Traders Expect Huge Moves in ArQule (ARQL) Stock

ArQule (ARQL) needs investors to pay close attention to the stock based on moves in the options market lately.

ARQL : 4.69 (-1.05%)
The Race to Treat Cancer, ArQule Inc. Continues Progress Across All Pipeline Assets

Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on ArQule Inc. (NASDAQ: ARQL), a bio-pharmaceutical...

ARQL : 4.69 (-1.05%)
Research Report Identifies Qudian Inc., ICICI Bank, Mobile TeleSystems OJSC, ArQule, Alibaba Group Holding, and Arcos Dorados with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Qudian Inc. (NYSE:QD), ICICI...

BABA : 202.21 (-1.95%)
ARQL : 4.69 (-1.05%)
QD : 10.19 (+2.10%)
ARCO : 7.15 (unch)
IBN : 8.77 (+0.69%)
MBT : 8.69 (-1.14%)
ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 23rd Congress of the European Hematology Association (EHA)

ArQule, Inc. (Nasdaq: ARQL) today announced clinical data from the company-sponsored ARQ 531-101 Phase 1 dose escalation study in subjects with relapsed or refractory hematologic malignancies...

ARQL : 4.69 (-1.05%)
ArQule to Present at the Jefferies 2018 Healthcare Conference on June 7, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at...

ARQL : 4.69 (-1.05%)
ArQule Strengthens Executive Team with Two Key Appointments

ArQule, Inc. (NASDAQ: ARQL) today announced two strategic additions to its executive team, appointing Dr. Marc Schegerin as senior vice president, corporate strategy, communication and finance,...

ARQL : 4.69 (-1.05%)
What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?

Merck's (MKGAF) Healthcare and Life Science segments to drive sales in Q1. However, operating expense is expected to be higher to support the launch of Bavencio and Mavenclad.

ARQL : 4.69 (-1.05%)
SMMT : 13.35 (+0.75%)
PFE : 36.30 (-0.44%)
MKGAF : 97.9250 (+0.80%)
ArQule Reports First Quarter 2018 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the first quarter of 2018.

ARQL : 4.69 (-1.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade ARQL with:

Business Summary

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage...

See More

Key Turning Points

2nd Resistance Point 5.06
1st Resistance Point 4.88
Last Price 4.69
1st Support Level 4.48
2nd Support Level 4.26

See More

52-Week High 6.07
Last Price 4.69
Fibonacci 61.8% 4.11
Fibonacci 50% 3.51
Fibonacci 38.2% 2.90
52-Week Low 0.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar